Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
Latest Information Update: 18 Jul 2024
At a glance
- Drugs SHR 6508 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 10 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2024 Status changed from not yet recruiting to recruiting.
- 07 Feb 2024 New trial record